Alan Crane

Title: The Innovative Contributions of Inventor Alan Crane

Introduction: Alan Crane, a prominent inventor based in Waban, Massachusetts, has made significant strides in the field of pharmaceutical formulations. With an impressive total of 14 patents to his name, Crane's work focuses on the development of innovative liquid protein formulations that enhance the delivery and efficacy of therapeutic proteins.

Latest Patents: Among his latest patents, one notable invention involves liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC). These concentrated, low-viscosity, low-volume liquid pharmaceutical formulations facilitate rapid and convenient administration via subcutaneous or intramuscular injection, as opposed to traditional intravenous infusion methods. The formulations encompass both low-molecular-weight and high-molecular-weight proteins, such as monoclonal antibodies (mAbs), and utilize viscosity-reducing ionic liquids.

Another pivotal patent by Crane centers on liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP). Similar to his previous inventions, these formulations are designed for quick administration through subcutaneous or intramuscular injections. They also incorporate organophosphates to significantly reduce viscosity, thereby improving patient comfort and treatment efficiency.

Career Highlights: Alan Crane has an established career, having contributed to notable companies in the biopharmaceutical sector, including Eagle Biologics, Inc. and Pandion Operations, Inc. His extensive experience in these organizations has equipped him with the knowledge and skills necessary to pioneer advancements in pharmaceutical formulations.

Collaborations: Throughout his career, Crane has collaborated with esteemed professionals such as Robert S. Langer and Alyssa M. Larson. Their collective expertise has fostered a productive environment for innovation, resulting in the development of cutting-edge pharmaceutical solutions.

Conclusion: Alan Crane's contributions to the field of liquid protein formulations have the potential to transform the way therapeutic proteins are administered. With a growing portfolio of patents, Crane continues to push the boundaries of innovation in the pharmaceutical industry, making him a noteworthy figure among contemporary inventors. His commitment to improving patient care through science is commendable and demonstrates the impactful role of inventors in healthcare advancements.